U.S. Building Stock News

QUALCOMM (QCOM) just logged its ninth straight quarter of topping both revenue and EPS expectations, and that consistency is exactly why investors are paying closer attention to the stock right now. See our latest analysis for QUALCOMM. The market seems to be catching on, with QUALCOMM’s share price up 16.68% on a year to date basis and its 3 year total shareholder return of 70.40% reflecting how investors have been rewarding its steady execution, ongoing acquisitions in AI and data center,...

Crown Castle (CCI) has quietly drifted lower over the past month, and that slide is prompting fresh questions about what investors are really paying for in this tower and fiber landlord. See our latest analysis for Crown Castle. That recent 4.4% 3 month share price pullback comes on top of a 1 year total shareholder return of negative 1.7% and a bruising negative 20.8% over three years. This suggests momentum is still fading as investors reassess tower growth and balance sheet risk. If Crown...

Texas Instruments (TXN) has been drifting slightly lower this week, but the bigger story sits beneath the share price. Even with a modest pullback, the chipmaker’s multiyear returns still outpace the broader market. See our latest analysis for Texas Instruments. The recent pullback leaves Texas Instruments’ share price at $177.99, after an 11.71% 1 month share price return that has eased off and a more muted 1 year total shareholder return of negative 3 percent. This suggests momentum is...

Mach Natural Resources (MNR) has been sliding, with shares down around 14% over the past 3 months and more than 30% this year, even as revenue and net income continue to grow. See our latest analysis for Mach Natural Resources. At the current share price of $11.71, the stock’s year to date share price return of negative 31.40 percent contrasts with a milder 1 year total shareholder return of negative 12.46 percent, suggesting sentiment has cooled even as fundamentals improve. If Mach’s recent...

In recent months, Nutanix completed a US$288.6 million share repurchase program covering 4,861,000 shares and announced new Nutanix Cloud Platform capabilities to support secure, compliant sovereign and distributed cloud deployments across major hyperscalers. The combination of capital returns via buybacks and expanded multi-cloud and AI-focused platform features underscores how Nutanix is trying to strengthen both shareholder value and its role in complex enterprise cloud...

Tradeweb Markets (TW) has quietly slid about 21% over the past year, even as its electronic trading platform continues to generate solid revenue and profit growth. This has created an interesting gap between share performance and business momentum. See our latest analysis for Tradeweb Markets. Despite the latest share price of $104.2 and a recent stretch of weaker momentum, including a double digit 3 month share price pullback, Tradeweb still boasts a strong three year total shareholder...

In November 2025, Robbins Geller Rudman & Dowd LLP began investigating Ardent Health, Inc. for potential U.S. securities law violations after the company missed third-quarter earnings due to heightened payor denials, adverse prior-period claim developments, and an accounting estimate change that brought forward revenue reserves. This combination of legal scrutiny and earlier revenue recognition raised fresh questions about Ardent Health’s disclosure practices, earnings quality, and the...

If you are wondering whether SLB is quietly becoming a value opportunity while the market is distracted, this article will walk you through whether the current price really lines up with the business behind the ticker. After a choppy few years, SLB has inched up 1.7% over the last week and 5.3% over the last month, while still only 0.6% higher over the past year despite being up 98.8% over five years. Recent headlines have focused on SLB doubling down on digital and low carbon technologies,...

If you are wondering whether Bristol-Myers Squibb at around $54 is a bargain or a value trap, you are not alone. This article is going to unpack that calmly and clearly. After a tough stretch, the stock has bounced with a 5.1% gain over the last week and a strong 16.4% move over the last 30 days, even though it is still down year to date and only modestly up over 1 year. This hints at shifting sentiment rather than a completed turnaround. That recent strength has come as investors refocus on...

Adtalem Global Education (ATGE) has quietly pushed higher, with the stock up about 5% over the past week and modestly positive this month, even after a steep slide in the past 3 months. See our latest analysis for Adtalem Global Education. At a share price of $97.76, Adtalem’s recent bounce, including a strong 1 day share price return and a solid year to date share price gain, contrasts with its sharp 90 day share price pullback. At the same time, its multi year total shareholder return...

Mobileye Global (MBLY) just picked up a meaningful real world win in Europe, with Ruter and Holo teaming up with Volkswagen owned MOIA to deploy ID. Buzz autonomous shuttles in Oslo using Mobileye Drive. See our latest analysis for Mobileye Global. That makes the Oslo win even more noteworthy, because it lands while sentiment has been weak, with a year to date share price return of minus 47.35 percent and a three year total shareholder return of minus 69.92 percent, suggesting long term...

Earlier this month, Bicara Therapeutics reported preliminary Phase 1b data showing that weekly 750 mg ficerafusp alfa plus pembrolizumab was generally well tolerated in first-line HPV-negative recurrent or metastatic head and neck squamous cell carcinoma, and the FDA granted the combination Breakthrough Therapy Designation in this setting. New biomarker findings suggesting stronger TGF-β inhibition and immune activation at the 1,500 mg dose level add scientific weight to Bicara’s ongoing...

Alphabet (GOOGL) has been on a strong run this year, and with shares up 63% year to date and about 23% over the past 3 months, investors are reassessing what they are really paying for. See our latest analysis for Alphabet. That surge in momentum, with a 30 day share price return of 11.51% and a 3 year total shareholder return of 251.14%, suggests investors are increasingly pricing Alphabet as a durable growth and AI infrastructure story rather than just a mature ad business. If Alphabet’s...

In 2025, MP Materials announced record rare earth production, new long-term agreements with the U.S. Department of Defense and Apple worth hundreds of millions of US dollars, and a Saudi refining joint venture backed by government funding to bolster non-Chinese supply chains. Together, these contracts, investments, and partnerships underline MP Materials’ emerging role as a core supplier in Western rare earth and magnet value chains, with government and blue-chip counterparties sharing both...

Chipotle Mexican Grill (CMG) just crossed a big psychological marker, opening its 4,000th restaurant in Manhattan, Kansas, and pairing that milestone with detailed plans for the next leg of its expansion. See our latest analysis for Chipotle Mexican Grill. The 4,000th store and fresh share repurchase firepower come after a choppy stretch, with a double digit 1 month share price return but a sharply negative year to date share price return and still solid multi year total shareholder returns...

If you have been wondering whether Duolingo at around $185 a share is now a bargain or still a pricey growth story, you are not alone. The stock has had a rough patch recently, down about 10.6% over the last week and roughly 42.9% year to date, even though it is still up around 158.3% over the past three years. That slide comes after a period when investors had priced Duolingo as a high growth, category defining language learning platform and are now reassessing what they are willing to pay...

Inspire Medical Systems (INSP) has experienced a volatile ride lately, with the stock dropping over the past week but still sitting well above where it traded a month ago. See our latest analysis for Inspire Medical Systems. Stepping back, that sharp 1 day and 7 day share price pullback comes after a powerful 30 day and 90 day rebound, but longer term total shareholder returns remain deeply negative. This suggests momentum is rebuilding from a still beaten up base. If Inspire’s recent swings...

PJT Partners (PJT) has quietly outperformed over the past year, with shares up about 4% and a strong 3 year total return above 130%. This raises fresh questions about whether the investment bank still looks reasonably priced. See our latest analysis for PJT Partners. The share price has drifted a little over the past quarter but still sits at around $170.03. That modest near term share price weakness contrasts with a much stronger three year total shareholder return, suggesting momentum has...

If you are wondering whether Liquidia is still a smart buy after its huge run, you are not alone. This is exactly the kind of stock where valuation really matters. The share price has pulled back about 2.3% over the last week, but it is still up 21.9% over 30 days and 182.6% year to date, with a 210.0% gain over the past year and 992.3% over five years. Those moves have been driven by growing optimism around Liquidia's pipeline and regulatory progress, with investors reacting positively to...

In the third quarter of 2025, Brandes Small Cap Value Fund disclosed a new position in Prestige Consumer Healthcare, while the company confirmed repurchasing about 4.7% of its shares since mid‑2024 for roughly US$161 million and reiterated fiscal 2026 revenue guidance that still points to a modest organic decline. Together, fresh institutional buying and ongoing buybacks highlight growing confidence in Prestige’s acquisition-led model and its focus on resilient, as-needed over-the-counter...

Genpact (G) just widened its leadership bench, adding three seasoned executives to drive its GenpactNext strategy and deepen its push into advanced AI led technology solutions and next generation clients. See our latest analysis for Genpact. The leadership refresh comes as Genpact’s share price hovers around $47.35, with a 90 day share price return of 14.57 percent and a 1 year total shareholder return of 10.14 percent, suggesting momentum is gradually building as investors reassess its AI...

Wondering if Ulta Beauty at around $591 a share is still worth buying, or if the big gains are already behind it? Let us unpack what the current price really implies about future returns. The stock has barely moved in the last week, but it is up 11.7% over the past month, 37.8% year to date, and 39.2% over the last year, with a 120.5% gain over five years that has rewarded long term holders. Those gains reflect growing confidence in Ulta's position as a go to beauty retailer, from its...

Many investors are wondering if CoreWeave is still a smart buy after its big run or if the easy money has already been made, and that is exactly what we are going to unpack here. The stock has cooled off recently, dropping about 16.1% over the last week and 6.5% over the past month, but it is still up an impressive 80.9% year to date, which suggests sentiment has shifted in a significant way. A lot of this volatility has been driven by headlines around AI infrastructure demand, fresh...

Opendoor Technologies (OPEN) just reshaped its C suite again, naming fintech veteran Lucas Matheson as President and confirming Christy Schwartz as permanent CFO. The company is sharpening its AI and blockchain focused turnaround narrative for investors. See our latest analysis for Opendoor Technologies. Those leadership moves land after a wild year, with the latest share price at $6.46 and a year to date share price return above 300%, but more recently a fading 30 day share price return and...